miRoncol Health is building a platform for AI-powered blood tests to democratize preventative healthcare based on microRNAs, the 2024 Nobel-recognized discovery. miRoncol is currently focusing on launching the first-of-its-kind patent pending multi-cancer risk assessment tests to provide an early warning of multiple cancers through regular checkups for the healthy population in Canada. miRoncol’s technology has demonstrated superior performance in peer-reviewed publications based on its proof-of-concept studies at about 90% sensitivity and less than 1% false positive rate across 10+ common solid tumors responsible for ~80% cancers except breast cancer. Leveraging existing blood test infrastructure and equipment, miRoncol Health brings an affordable and accurate category defining solution to enable more cancer early detection to save more lives.